The pattern analysis and computational biology core (core B) will provide computational and statistical support to this program project grant. The core will also provide web resources for storing and sharing data and information and a tissue database developed for a Gl-spore grant for pancreatic tissues. The major goal is to discover patterns of genetic/expression/amplification change in pancreaticcancer cells and tissues that are predictive for therapeutic choice or clinical outcome. By storing data in descriptive object formats and using novel computational tools, patterns that will be most useful for clinical applications will be identified and carefully validated. Through additional bioinformatics support and genome analysis,these results will be used to discover potential drug targets. In project 1, statistical support for the analysis of immunohistochemical measurements designed to explore redox control in pancreatic cancer tissues will be provided. In project 2, studies of the effects of large numbers of agents on mutant cell lines will be supported by providing suitable data storage, additional information about the drugs and chemicals, and prediction of the cellular functions and pathways that might be affected by the presence of the tumor suppressor mutations. In project 3, in addition to data storage, support will be provided for the identification of changes in gene number and expression and the effect of these changes on biochemical pathways and drug sensitivities. Interactive maps of the human genome will be prepared for displaying the principal genetic, gene amplification/loss, expression data, and mutationalchanges in pancreatic cells that are being discovered in this project and others will be developed. Data objects will be developed to model all project data in order to facilitate pattern searching that will facilitate identifying new drug targets. Through additionalbioinformatics support and genome analysis, we will help to rationalize the kinds of alterations in nucleotide and DNA metabolism that influence the effects of gemcitabineand any other new drugs discovered on this program project grant on pancreatic cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA109552-04
Application #
7666110
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
4
Fiscal Year
2008
Total Cost
$263,786
Indirect Cost
Name
Translational Genomics Research Institute
Department
Type
DUNS #
118069611
City
Phoenix
State
AZ
Country
United States
Zip Code
85004
Grandjean, Geoffrey; de Jong, Petrus R; James, Brian et al. (2016) Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1? Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target. Cancer Res 76:4259-4269
Samulitis, Betty K; Pond, Kelvin W; Pond, Erika et al. (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16:43-51
Sinha, Arkadeep; Cherba, David; Bartlam, Heather et al. (2014) Mesenchymal-like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial-like counterparts. Mol Oncol 8:1253-65
Whatcott, Clifford; Han, Haiyong; Posner, Richard G et al. (2013) Tumor-stromal interactions in pancreatic cancer. Crit Rev Oncog 18:135-51
Spivak-Kroizman, Taly R; Hostetter, Galen; Posner, Richard et al. (2013) Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res 73:3235-47
Dorr, Robert T; Samulitis, Betty K; Wisner, Lee et al. (2013) Characterization of a membrane-active anti-tumor agent, UA8967. Invest New Drugs 31:576-86
Landowski, Terry H; Samulitis, Betty K; Dorr, Robert T (2013) The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers. Invest New Drugs 31:1616-25
Liang, Winnie S; Craig, David W; Carpten, John et al. (2012) Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One 7:e43192
Provenzano, Paolo P; Cuevas, Carlos; Chang, Amy E et al. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21:418-29
Xie, Lifang; Kassner, Michelle; Munoz, Ruben M et al. (2012) Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem Pharmacol 83:452-61

Showing the most recent 10 out of 59 publications